Cargando…
A Real-World Observational Study of the Use and Associated Costs of Treating Neuroendocrine Tumors With Somatostatin Analogs in Canada
Somatostatin analogs (SSAs; lanreotide autogel and octreotide long-acting release) are used to treat neuroendocrine tumors; however, factors that influence SSA use are unclear. METHODS: This real-world, observational study collected data from private/public pharmacy claims for patients using SSAs in...
Autores principales: | Cheung, Winson Y., LaForty, Callahan, Liovas, Anna, McKechnie, Heather, Loree, Jonathan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144276/ https://www.ncbi.nlm.nih.gov/pubmed/37078938 http://dx.doi.org/10.1097/MPA.0000000000002144 |
Ejemplares similares
-
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022) -
Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada
por: Ding, Philip Q., et al.
Publicado: (2022) -
Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
por: Baldelli, Roberto, et al.
Publicado: (2014) -
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
por: Darden, Christina, et al.
Publicado: (2021) -
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors’ perspective
por: Wills, Allison, et al.
Publicado: (2023)